STAGE III LUNG CANCER AJCC V8

This early-phase study is testing a personalized vaccine made from each patient's unique tumor mutations. The goal is to see if it is safe and can help the immune system fight advanced breast cancer, melanoma, and non-small cell lung cancer. About 25 adults whose cancers have spr…

This study tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control tumor growth in people with advanced lung cancer whose disease is starting to worsen on immunotherapy alone. About 20 adults with stage III or IV non-small cell lung cancer will re…

This study tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. About 37 adul…

This study tests whether adding local treatments (like surgery or radiation) to the immunotherapy drug durvalumab can help control stage III lung cancer that has started to grow again after standard treatment. About 51 adults whose cancer has progressed after chemoradiation and d…

This study tests if a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) can help people with a specific genetic type of advanced lung cancer (LKB1-mutant) that has stopped responding to standard treatments. The trial will enroll 50 …

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…

This study tests a new drug combination (GT103 plus pembrolizumab) for people with advanced non-small cell lung cancer that has a specific genetic change called STK11 mutation. The goal is to see if adding GT103 can help shrink tumors or slow the cancer's growth. About 28 adults …

This study tests whether giving two immunotherapy drugs (cemiplimab and fianlimab) before surgery can kill more cancer cells in people with early-stage non-small cell lung cancer. About 60 adults with stage IB to IIIB lung cancer will receive the drug combination, then have their…

This early-phase study tests whether combining two drugs, carfilzomib and sotorasib, is safe and effective for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 15 adults who have already tried a KRAS inhibitor will receive the combinat…

This study tests whether adding an experimental drug called TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can better shrink tumors and extend life in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, maki…

This study tests whether adding a precise, high-dose radiation treatment (SBRT) to the tumor before standard chemoradiation and immunotherapy can help people with locally advanced lung cancer live longer. About 474 adults whose lung cancer has spread to nearby lymph nodes but can…

This study tests whether the drug canakinumab can prevent lung cancer in people who have suspicious lung nodules that haven't gone away. About 50 participants will receive the drug to see if their nodules shrink or disappear, and to track how many develop lung cancer over time. T…

This study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…

This study tests whether a home-based breathing exercise program can help lung cancer survivors (stages I-III) who often struggle with shortness of breath, fatigue, and low fitness after surgery. About 100 participants will do breathing exercises regularly for several weeks. Rese…

This study tests a smarter way to give radiation to people with lung cancer. Normally, the radiation plan is made before treatment starts, but tumors can shrink during treatment, which may expose healthy tissue to unnecessary radiation. In this study, the radiation plan is update…

This study tests whether a special yoga program can improve physical function, fatigue, sleep, and quality of life for people with lung or esophageal cancer who are getting radiation therapy, and also for their family caregivers. About 400 patient-caregiver pairs will take part. …

This study looks at how immune cells called T cells change in people with advanced melanoma, lung cancer, or other solid tumors during anti-PD-1 treatment. Researchers will measure specific markers in blood samples to see if they can predict whether the therapy is working or if r…

This study looks at how chemoradiation for locally advanced lung cancer affects the heart. Researchers will track heart injury and fitness in 100 patients, using each person's risk profile to tailor treatment and potentially reduce heart damage. The goal is to learn how to better…

This study looks at two different ways surgeons cut blood vessels during lung cancer surgery. The goal is to see if tying off the vein first (instead of the artery) reduces the amount of tumor DNA released into the bloodstream. About 100 adults with early-stage lung cancer will h…

This study tests a conversation aid that helps lung cancer patients and their doctors make treatment decisions together. About 100 patients with advanced non-small cell lung cancer will use the tool during appointments to see if it improves shared decision-making and satisfaction…

This study looks at how the bacteria in your gut might influence stomach issues like diarrhea and colitis caused by certain cancer drugs (immune checkpoint inhibitors). Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or genito…